Immune inflammation indicators in anal cancer patients treated with concurrent chemoradiation: training and validation cohort with online calculator (ARC: Anal Cancer Response Classifier)

References

• National Comprehensive Cancer Network. Anal carcinoma. Version 2.2017. [ Online 204, 2017]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/anal_blocks.pdf.
   Google Scholar
• Daling JR, Madeleine MM, Johnson LG, et al. Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer. Cancer. 2004;101:270–280. doi:10.1002/cncr.20365. 15241823
   PubMed Web of Science ®Google Scholar
• Frisch M, Glimelius B, van Den Brule AJ, et al. Sexually transmitted infection as a cause of anal cancer. N Engl J Med. 1997;337:1350–1358. doi:10.1056/NEJM199711063371904. 9358129
   PubMed Web of Science ®Google Scholar
• Grulich AE, Poynten IM, Machalek DA, Jin F, Templeton DJ, Hillman RJ. The epidemiology of anal cancer. Sex Health. 2012;9:504–508. doi:10.1071/SH12070. 22958581
   PubMed Web of Science ®Google Scholar
• Ryan DP, Compton CC, Mayer RJ. Carcinoma of the anal cancer. N Engl J Med. 2000;342:792–800. doi:10.1056/NEJM200003163421107. 10717015
   PubMed Web of Science ®Google Scholar
• Nigro ND, Vaitkevicius VK, Considine B. Combeined therapy for cancer of the anal canal: a preliminary report. Dis Colon Rectum. 1974;17:354–356. 4830803
   PubMed Web of Science ®Google Scholar
• Uronis HE, Bendell JC. Anal cancer: an overview. Oncologist. 2007;12:524–534. doi:10.1634/theoncologist.12-5-524. 17522240
   PubMed Web of Science ®Google Scholar
• Gastr. Bartelink H, Roelofsen F, Eschwege F, et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a Phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol. 1997;15:2040–2049. doi:10.1200/JCO.1997.15.5.2040. 9164216
   PubMed Web of Science ®Google Scholar
• Mullen JT, Rodriguez-Bigas MA, Chang GJ, et al. Results of surgical salvage after failed chemoradiation therapy for epidermoid carcinoma of the anal canal. Ann Surg Oncol. 2007;14:478–483. doi:10.1245/s10434-006-9221-717103253
   PubMed Web of Science ®Google Scholar
• Faivre C, Rougier P, Ducreux M, et al. 5-Fluorouracile and cisplatinum combination chemotherapy for metastatic squamous-cell anal cancer. Bull Cancer. 1999;86:861–865. 10572237
   PubMed Web of Science ®Google Scholar
• Jaiyesimi IA, Pazdur R. Cisplatin and 5-fluorouracil as salvage therapy for recurrent metastatic squamous cell carcinoma of the anal canal. Am J Clin Oncol. 1993;16:536–540. 8256774
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–674. doi:10.1016/j.cell.2011.02.013. 21376230
   PubMed Web of Science ®Google Scholar
• Nozoe T, Matsumata T, Kitamura M, Sugimachi K. Significance of preoperative elevation of serum C-reactive protein as an indicator for prognosis in colorectal cancer. Am J Surg. 1998;176:335–338. 9817250
   PubMed Web of Science ®Google Scholar
• Toiyama Y, Inoue Y, Saigusa S, et al. C-reactive protein as predictor of recurrence in patients with rectal cancer undergoing chemoradiotherapy followed by surgery. Anticancer Res. 2013;33:5065–5074. 24222151
   PubMed Web of Science ®Google Scholar
• Shibutani M, Maeda K, Nagahara H, et al. Prognostic significance of the preoperative serum C-reacrive protein level in patients with stage IV colorectal cancer. Surg Today. 2015;45(3):315–321. doi:10.1007/s00595-014-0909-1. 24817059
   PubMedGoogle Scholar
• Feng JF, Chen S, Yang X. Systemic immune-inflammation index (SII) is a useful prognostic indicator for patients with squamous cell carcinoma of the esophagus. Medicine. 2017;96:1–6. doi:10.1097/MD.0000000000005886.
   Web of Science ®Google Scholar
• Hong X, Cui B, Wang M, et al. Systemic immune-inflammation index, based on platelet counts and neutrophil-lymphocyte ratio, is useful for predicting prognosis in small cell lung cancer. Tohoku J Exp Med 2015;236(4):297–304.
   Google Scholar
• Martin D, Rödel F, Winkelmann R, Balermpas P, Rödel C, Fokas E. Peripheral leukocytosis is inversely correlated with intratumoral CD8+ T-cell infiltration and associated with worse outcome after chemoradiotherapy in anal cancer. Front Immunol. 2017;8:1225. doi:10.3389/fimmu.2017.01225. 29085358
   PubMed Web of Science ®Google Scholar
• Glynne-Jones R, Sebag-Montefiore D, Adams R, et al. Prognostic factors for recurrence and survival in anal cancer: generating hypotheses from the mature outcomes of the first United Kingdom Coordinating Committee on Cancer Research Anal Cancer Trial (ACT I). Cancer. 2013;119(4):748–755. doi:10.1002/cncr.27825. 23011911
   PubMed Web of Science ®Google Scholar
• Casadei Gardini A, Scarpi E, Faloppi L, et al. Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib. Oncotarget. 2016;7(41):67142–67149. doi:10.18632/oncotarget.11565. 27613839
   PubMedGoogle Scholar
• Bruix J, Cheng A-L, Meinhardt G, Nakajima K, De Sanctis Y, Llovet J. Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: analysis of two Phase III studies. J Hepatol. 2017;67(5):999–1008. doi:10.1016/j.jhep.2017.06.026. 28687477
   PubMed Web of Science ®Google Scholar
• Toh E, Wilson J, Sebag-Montefiore D, Botterill I. Neutrophil:lymphocyteratio as a simple and novel biomarker for prediction of locoregionalrecurrence after chemoradiotherapy for squamous cell carcinoma of the anus. Colorectal Dis. 2014;16(3):O90–O97. doi:10.1111/codi.12467. 24148256
   PubMed Web of Science ®Google Scholar
• Kachnic LA, Winter K, Myerson RJ, et al. RTOG 0529: a Phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mytomycin C for the reduction of acute morbidity in carcinoma of the anal canal. Int J Radiat Oncol Biol Phys. 2013;86:27–33. doi:10.1016/j.ijrobp.2012.09.023. 23154075
   PubMed Web of Science ®Google Scholar
• Franco P, Arcadipane F, Ragona R, et al. Volumetric modulated arc therapy (VMAT) in the combined modality treatment of anal cancer patients. Br J Radiol. 2016;89:2015832. doi:10.1259/bjr.20150832.
   Web of Science ®Google Scholar
• Arcadipane F, Franco P, Ceccarelli M, et al. Image-guided IMRT with simultaneous integrated boost as per RTOG 0529 for the treatment of anal cancer. Asia Pac J Clin Oncol. 2018;14:217–223. doi:10.1111/ajco.12768. 28856848
   PubMed Web of Science ®Google Scholar
• Hoff CM. Importance of hemoglobin concentration and its modification for the outcome of head and neck cancer patients treated with radiotherapy. Acta Oncol. 2012;51:419–432. doi:10.3109/0284186X.2011.653438. 22313317
   PubMed Web of Science ®Google Scholar
• Roldan GB, Chan AK, Buckner M, et al. The prognostic value of hemoglobin in patients with anal cancer treated with chemoradiotherapy. Dis Colon Rectum. 2010;53:1127–1134. doi:10.1007/DCR.0b013e3181d964c1. 20628275
   PubMed Web of Science ®Google Scholar
• Franco P, Montagnani F, Arcadipane F, et al. The prognostic role of hemoglobin levels in patients undergoing concurrent chemo-radiation for anal cancer. Radiat Oncol. 2018;13(1):83. doi:10.1186/s13014-018-1035-9. 29720197
   PubMedGoogle Scholar
• Diakos CI, Charles KA, McMillan DC, Clarke SJ. Cancer-related inflammation and treatment eff ectiveness. Lancet Oncol. 2014;15:e493–e503. doi:10.1016/S1470-2045(14)70263-3. 25281468
   PubMed Web of Science ®Google Scholar
• Balermpas P, Martin D, Wieland U, et al. Human papilloma virus load and PD-1/PD-L1, CD8 and FOXP3 in anal cancer patients treated with chemoradiotherapy: rationale for immunotherapy. Oncoimmunology. 2017;6(3):e1288331. doi:10.1080/2162402X.2017.1288331. 28405521
   PubMed Web of Science ®Google Scholar
• Zhao Y-J, Sun W-P, Peng J-H, et al. Programmed death-ligand 1 expression correlates with diminished CD8+ T cell infiltration and predicts poor prognosis in anal squamous cell carcinoma patients. Cancer Manag Res. 2018;10:1–11. doi:10.2147/CMAR.S153965. 29296096
   PubMed Web of Science ®Google Scholar
• Govindarajan R, Gujja S, Siegel ER, et al. Programmed cell death-ligand 1 (PD-L1) expression in anal cancer. Am J Clin Oncol. 2018;41(7):638–642.
   Web of Science ®Google Scholar
• Ott PA, Piha-Paul SA, Munster P, et al. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal. Annal Oncol. 2017;28:1036–1041. doi:10.1093/annonc/mdx029.
   PubMed Web of Science ®Google Scholar
• Pm H. Pathobiology of the neutrophil-intestinal epithelial cell interaction: role in carcinogenesis. World J Gastroenterol. 2010;16:5790–5800. 21154999
   PubMed Web of Science ®Google Scholar
• Nind AP, Nairn RC, Rolland JM, Guli EP, Hughes ES. Lymphocyte anergy in patients with carcinoma. Br J Cancer. 1973;28:108–117. 4581078
   PubMed Web of Science ®Google Scholar
• Calman KC. Tumour immunology and the gut. Gut. 1975;16:490–499. 50255
   PubMed Web of Science ®Google Scholar
• De Giorgi U, Mego M, Scarpi E, et al. Relationship between lymphocytopenia and circulating tumor cells as prognostic factors for overall survival in metastatic breast cancer. Clin Breast Cancer. 2012;12:264–269. doi:10.1016/j.clbc.2012.04.004. 22591634
   PubMed Web of Science ®Google Scholar
• Ogino S, Nosho K, Irahara N, et al. Lymphocytic reaction to colorectal cancer is associated with longer survival, indepent of lymph node count, microsatellite instability and CpG island methylator phenotype. Clin Cancer Res. 2009;15:6412–6420. doi:10.1158/1078-0432.CCR-09-1438. 19825961
   PubMed Web of Science ®Google Scholar
• Waldner M, Schimanski CC, Neurath MF. Colon cancer and the immune system: the role of tumor invading T cells. World J Gastroenterol. 2006;12:7233–7238. 17143936
   PubMed Web of Science ®Google Scholar
• Ropponen KM, Eskelinen MJ, Lipponen PK, Alhava E, Kosma VM. Prognostic value of tumour-infiltrating lymphocytes (TILs) in colorectal cancer. J Pathol. 1997;182:318–324. doi:10.1002/(SICI)1096-9896(199707)182:3<318::AID-PATH862>3.0.CO;2-6. 9349235
   PubMed Web of Science ®Google Scholar
• Schernberg A, Escande A, Rivin Del CE, et al. Leukocytosis and neutrophilia predicts outcome in anal cancer. Radiother Oncol. 2017;122:137–145. doi:10.1016/j.radonc.2016.12.009. 28024835
   PubMed Web of Science ®Google Scholar
• Schernberg A, Huguet F, Moureau-Zabotto L, et al. External validation of leukocytosis and neutrophilia as a prognostic marker in anal carcinoma treated with definitve chemoradiation. Radiother Oncol. 2017;124:110–117. doi:10.1016/j.radonc.2017.06.009. 28662871
   PubMed Web of Science ®Google Scholar
• Banerjee R, Roxin G, Eliasziw M, et al. The prognostic significance of pretreatment leukocytosis in patients with anal cancer treated with radical chemoradiotherapy or radiotherapy. Dis Colon Rectum. 2013;56:21036–21042. doi:10.1097/DCR.0b013e31829ab0d4.
   Web of Science ®Google Scholar
• Labelle M, Begum S, Hynes RO. Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell. 2011;20:576–590. doi:10.1016/j.ccr.2011.09.009. 22094253
   PubMed Web of Science ®Google Scholar
• Franco P, Mistrangelo M, Arcadipane F, et al. Intensity-modulated radiation therapy with simultaneous integrated boost combined with concurrent chemotherapy for the treatment of anal cancer patients: 4-year results of a consecutive case series. Cancer Invest. 2015;33(6):259–266. doi:10.3109/07357907.2015.1028586.
   Google Scholar